A trial update was recorded on August 21, 2026 for a study relevant to glucagon and type 1 diabetes management. The trial, registered as NCT07061574, is titled "A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes." The study is listed in Phase 1/2 and its current status is recruiting.
This trial is evaluating low dose anti-thymocyte globulin followed by either adalimumab or verapamil in individuals with new onset type 1 diabetes. Glucagon, an approved compound, is physiologically relevant to type 1 diabetes management, which is the context for tracking this update. No outcome data, efficacy results, or safety findings have been reported for this trial at this stage.
The listed status reflects that the trial is actively recruiting participants as of the date given. No additional details about enrollment numbers, trial sites, or timelines were included in this update. Readers interested in the broader context of glucagon as an approved compound can consult the compound overview.